• Je něco špatně v tomto záznamu ?

Membrane and soluble Toll-like receptor 2 in patients with psoriasis treated by Goeckerman therapy

K. Kondelkova, J. Krejsek, L. Borska, Z. Fiala, K. Hamakova, K. Ettler, C. Andrys,

. 2014 ; 53 (11) : e512-7. [pub] 20140930

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15031823

BACKGROUND: Toll-like receptor (TLR) 2 belongs to the large TLR receptor family comprised of at least 10 members with different roles in innate immunity. Psoriasis is recognized as a T-cell driven immune-mediated systemic inflammatory disease with a skin manifestation. An effective therapeutic approach to treat psoriasis is Goeckerman therapy (GT). The aim of this study was to assess both the kinetics of the expression of TLR2 on blood cells and the concentration of soluble (s)TLR2 in serum of patients with psoriasis and to examine the effect of GT on both TLR2 expression and sTLR2 level. METHODS: Both membrane and sTLR2 were determined in 20 patients and 20 healthy controls. sTLR2 was evaluated by enzyme-linked immunosorbent assay. Flow cytometry method was used to determine the expression of membrane TLR2 of monocytes and granulocytes. RESULTS: The serum level of sTLR2 was significantly lower (P < 0.0001) in patients both before and after GT compared to the control group. Compared to the membrane expression of TLR2 on monocytes of healthy blood donors, TLR2 expression was significantly higher in patients both before and after GT (P = 0.0001). Similarly, TLR2 expression on granulocytes was significantly higher in patients both before (P = 0.0061) and after (P < 0.0001) therapy than in control. CONCLUSIONS: Membrane and soluble TLR2 may be involved in the pathogenesis of psoriasis. Both remained unchanged by GT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031823
003      
CZ-PrNML
005      
20151013095850.0
007      
ta
008      
151005s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ijd.12381 $2 doi
035    __
$a (PubMed)25266302
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kondelkova, Katerina $u Department of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic.
245    10
$a Membrane and soluble Toll-like receptor 2 in patients with psoriasis treated by Goeckerman therapy / $c K. Kondelkova, J. Krejsek, L. Borska, Z. Fiala, K. Hamakova, K. Ettler, C. Andrys,
520    9_
$a BACKGROUND: Toll-like receptor (TLR) 2 belongs to the large TLR receptor family comprised of at least 10 members with different roles in innate immunity. Psoriasis is recognized as a T-cell driven immune-mediated systemic inflammatory disease with a skin manifestation. An effective therapeutic approach to treat psoriasis is Goeckerman therapy (GT). The aim of this study was to assess both the kinetics of the expression of TLR2 on blood cells and the concentration of soluble (s)TLR2 in serum of patients with psoriasis and to examine the effect of GT on both TLR2 expression and sTLR2 level. METHODS: Both membrane and sTLR2 were determined in 20 patients and 20 healthy controls. sTLR2 was evaluated by enzyme-linked immunosorbent assay. Flow cytometry method was used to determine the expression of membrane TLR2 of monocytes and granulocytes. RESULTS: The serum level of sTLR2 was significantly lower (P < 0.0001) in patients both before and after GT compared to the control group. Compared to the membrane expression of TLR2 on monocytes of healthy blood donors, TLR2 expression was significantly higher in patients both before and after GT (P = 0.0001). Similarly, TLR2 expression on granulocytes was significantly higher in patients both before (P = 0.0061) and after (P < 0.0001) therapy than in control. CONCLUSIONS: Membrane and soluble TLR2 may be involved in the pathogenesis of psoriasis. Both remained unchanged by GT.
650    _2
$a dospělí $7 D000328
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a buněčná membrána $x chemie $7 D002462
650    _2
$a dehet uhelný $x terapeutické užití $7 D003033
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a granulocyty $x chemie $7 D006098
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a keratolytika $x terapeutické užití $7 D007641
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a monocyty $x chemie $7 D009000
650    12
$a fotochemoterapie $7 D010778
650    _2
$a psoriáza $x krev $x farmakoterapie $7 D011565
650    _2
$a toll-like receptor 2 $x analýza $x krev $7 D051195
650    12
$a terapie ultrafialovými paprsky $7 D014467
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krejsek, Jan
700    1_
$a Borska, Lenka
700    1_
$a Fiala, Zdenek
700    1_
$a Hamakova, Kveta
700    1_
$a Ettler, Karel
700    1_
$a Andrýs, Ctirad $7 mzk2008430528
773    0_
$w MED00009891 $t International journal of dermatology $x 1365-4632 $g Roč. 53, č. 11 (2014), s. e512-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25266302 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151013100039 $b ABA008
999    __
$a ok $b bmc $g 1092699 $s 914949
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 53 $c 11 $d e512-7 $e 20140930 $i 1365-4632 $m International journal of dermatology $n Int J Dermatol $x MED00009891
LZP    __
$a Pubmed-20151005

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...